SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
June 10 2024 - 8:30AM
SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical)
announces that three new members have joined its Board of
Directors. Two new directors, Jennifer A. Baird and Bernadette N.
Vincent, were elected at the Company’s 2024 Annual Meeting of
Stockholders held on June 4, and John Neuman was appointed to the
Board on June 5. Former directors Bruce Rodgers and Richard Russell
did not stand for reelection at the 2024 Annual Meeting, and Andres
Lobo announced his retirement from Dow Chemical, resulting in his
departure from the SeaStar Medical Board.
“We are delighted to add three outstanding
professionals in Jennifer, Bernadette and John to our Board,” said
Rick Barnett, SeaStar Medical’s Chairman. “Our new Directors bring
significant leadership, financial and formidable industry
experience that will be highly valuable as SeaStar Medical
continues its transition to a commercial-stage company. We look
forward to their contributions. On behalf of the Board, I’d like to
express our appreciation for the services provided by Andres, Bruce
and Richard.”
Ms. Baird serves as the Executive Chair of
Culturewell, Co., an organization that delivers actionable insight
for healthcare infection prevention through environmental sampling
testing and germ risk assessments. She previously was CEO and
Director of the medical device software company Fifth Eye Inc. and
CEO and Director of the renewable energy technology company Accio
Energy, Inc. Prior to that, Ms. Baird co-founded and served as CEO
and Director at the healthcare-based companies Accuri Cytometers,
Inc. (acquired by Becton Dickinson) and Sonetics Ultrasound, Inc.
She serves as a Director for the non-profit Hope Clinic and advisor
for the Michigan Founders Fund. Ms. Baird holds a BA in
organizational psychology/leadership from the University of
Michigan and an MBA from the Kellogg Graduate School of Management
at Northwestern University.
Ms. Vincent most recently held executive roles
including President, Chief Operating Officer and Chief Field
Operations Officer and was a Director at Satellite Healthcare Inc.,
a national non-profit kidney care company. She served on the
Quality, Safety & Patient Experience and the Government &
Compensation Executive & Strategy committees. Prior to that,
Ms. Vincent was Chief Operating Officer for Mednax, Inc., a
provider of multi-specialty physician and health system services
and held various leadership positions with Fresenius Medical Care
North America, including Group Vice President and Vice President of
Operations. Ms. Vincent is a Director for the National Kidney
Foundation, California & Pacific Northwest Chapter and was
Founder-Board member for the Laureate Academy Charter School. She
holds a BS in nursing from Dillard University and an MBA from
Pepperdine University.
Mr. Neuman retired from The Dow Chemical Company
in 2023 following 30 years of service, most recently as Vice
President of Global Financial Accounting. In this position, he
directed a team of approximately 350 professionals with
responsibilities for financial accounting and reporting for a
global network of more than 400 legal entities, including SEC
filings. His tenure at Dow included finance integration and
reporting responsibilities for several transactions, including the
Rohm & Haas and Dow Corning acquisitions, and the Dow/DuPont
merger. Prior to joining Dow, Mr. Neuman was an audit manager for
Deloitte & Touche LLP. He holds a degree in accounting from
Michigan State University, is a member of the Michigan State
University External Advisory Board for the Department of Accounting
and Information Systems and is a Certified Public Accountant
(inactive).
About SeaStar Medical
SeaStar Medical is a commercial-stage medical
technology company that is redefining how extracorporeal therapies
may reduce the consequences of excessive inflammation on vital
organs. SeaStar Medical’s novel technologies rely on science and
innovation to provide life-saving solutions to critically ill
patients. The Company is developing and commercializing
cell-directed extracorporeal therapies that target the effector
cells that drive systemic inflammation, causing direct tissue
damage and secreting a range of pro-inflammatory cytokines that
initiate and propagate imbalanced immune responses. For more
information visit www.seastarmedical.com or visit us on LinkedIn or
X.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1955.
These forward-looking statements include, without limitation,
SeaStar Medical’s expectations with respect to the ability to
successfully commercialize SCD products and contribution by board
members. Words such as “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside SeaStar Medical’s control and are
difficult to predict. Factors that may cause actual future events
to differ materially from the expected results include, but are not
limited to: (i) the risk that SeaStar Medical may not be able to
obtain regulatory approval of its SCD product candidates; (ii) the
risk that SeaStar Medical may not be able to raise sufficient
capital to fund its operations, including current or future
clinical trials; (iii) the risk that SeaStar Medical and its
current and future collaborators are unable to successfully develop
and commercialize its products or services, or experience
significant delays in doing so, including failure to achieve
approval of its products by applicable federal and state
regulators, (iv) the risk that SeaStar Medical may never achieve or
sustain profitability; (v) the risk that SeaStar Medical may not be
able to access funding under existing agreements; (vi) the risk
that third-parties suppliers and manufacturers are not able to
fully and timely meet their obligations, (vii) the risk of product
liability or regulatory lawsuits or proceedings relating to SeaStar
Medical’s products and services, (viii) the risk that SeaStar
Medical is unable to secure or protect its intellectual property,
and (ix) other risks and uncertainties indicated from time to time
in SeaStar Medical’s Annual Report on Form 10-K, including those
under the “Risk Factors” section therein and in SeaStar Medical’s
other filings with the SEC. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and SeaStar Medical assumes no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
SeaStar Medical Contact:
LHA Investor Relations Jody Cain (310)
691-7100 Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Jul 2024 to Aug 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Aug 2023 to Aug 2024